ARGONAUT-I: Activity of cefiderocol (s-649266), a siderophore cephalosporin, against gram-negative bacteria, including carbapenem-resistant nonfermenters and enterobacteriaceae with defined extended-spectrum β-lactamases and carbapenemases

Antimicrobial Agents and Chemotherapy

Volumn 63, Issue 1, 2019, Pages

  Jacobs, Michael R ^a,b   Abdelhamed, Ayman M ^a,b   Good, Caryn E ^a,b   Rhoads, Daniel D ^a,b   Hujer, Kristine M ^a,c   Hujer, Andrea M ^a,c   Domitrovic, T Nicholas ^a,c   Rudin, Susan D ^a,c   Richter, Sandra S ^d   van Duin, David ^e   Kreiswirth, Barry N ^f   Greco, Chris ^g   Fouts, Derrick E ^g   Bonomo, Robert A ^a,c  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^c LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^f PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

^g J CRAIG VENTER INSTITUTE   (United States)

Author keywords

Cefiderocol; Cephalosporin; Enterobacteriaceae; Gram negative bacteria; S 649266; Siderophore

Indexed keywords

AMIKACIN; AVIBACTAM PLUS CEFTAZIDIME; AZTREONAM; BETA LACTAMASE KPC; BETA LACTAMASE SHV; BETA LACTAMASE TEM 1; CARBAPENEMASE; CEFEPIME; CEFIDEROCOL; CEFTAZIDIME; CEFTOLOZANE PLUS TAZOBACTAM; CIPROFLOXACIN; COLISTIN; EXTENDED SPECTRUM BETA LACTAMASE; MEROPENEM; TIGECYCLINE; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; BETA LACTAMASE; CEPHALOSPORIN DERIVATIVE; SIDEROPHORE;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATE; BROTH DILUTION; CARBAPENEM RESISTANT ACINETOBACTER BAUMANNII; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; IN VIVO STUDY; MIC90; NON-FERMENTING GRAM-NEGATIVE BACTERIUM; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STENOTROPHOMONAS MALTOPHILIA; WHOLE GENOME SEQUENCING; ACINETOBACTER BAUMANNII; BETA-LACTAM RESISTANCE; CULTURE MEDIUM; DRUG EFFECT; ENTEROBACTERIACEAE; ENZYMOLOGY; GENE EXPRESSION; GENETICS; GRAM NEGATIVE INFECTION; GROWTH, DEVELOPMENT AND AGING; HUMAN; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY;

ACINETOBACTER BAUMANNII; ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; CEPHALOSPORINS; CULTURE MEDIA; ENTEROBACTERIACEAE; GENE EXPRESSION; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; SIDEROPHORES; STENOTROPHOMONAS MALTOPHILIA;

EID: 85058915073     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01801-18     Document Type: Article

References (30)

1. World Health Organization. 2017. Antibacterial agents in clinical development. An analysis of the antibacterial clinical development pipeline, including tuberculosis. Report WHO/EMP/IAU/201711. World Health Organization, Geneva, Switzerland.
2. Centers for Disease Control and Prevention. 2013. Antibiotic resistance threats in the United States, 2013. Centers for Disease Control and Prevention, Atlanta, GA. https://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf.
3. Doi Y, Bonomo RA, Hooper DC, Kaye KS, Johnson JR, Clancy CJ, Thaden JT, Stryjewski ME, van Duin D, for the Gram-Negative Committee of the Antibacterial Resistance Leadership Group (ARLG). 2017. Gram-negative bacterial infections: Research priorities, accomplishments, and future directions of the Antibacterial Resistance Leadership Group. Clin Infect Dis 64:S30 -S35. https://doi.org/10.1093/cid/ciw829.
4. Rojas LJ, Salim M, Cober E, Richter SS, Perez F, Salata RA, Kalayjian RC, Watkins RR, Marshall S, Rudin SD, Domitrovic TN, Hujer AM, Hujer KM, Doi Y, Kaye KS, Evans S, Fowler VG, Jr, Bonomo RA, van Duin D, Antibacterial Resistance Leadership Group. 2017. Colistin resistance in carbapenemresistant Klebsiella pneumoniae: Laboratory detection and impact on mortality. Clin Infect Dis 64:711-718. https://doi.org/10.1093/cid/ciw805.
5. Wright MS, Iovleva A, Jacobs MR, Bonomo RA, Adams MD. 2016. Genome dynamics of multidrug-resistant Acinetobacter baumannii during infection and treatment. Genome Med 8:26. https://doi.org/10.1186/s13073 -016-0279-y.
6. Evans SR, Hujer AM, Jiang H, Hill CB, Hujer KM, Mediavilla JR, Manca C, Tran TT, Domitrovic TN, Higgins PG, Seifert H, Kreiswirth BN, Patel R, Jacobs MR, Chen L, Sampath R, Hall T, Marzan C, Fowler VG, Jr, Chambers HF, Bonomo RA. 2017. Informing antibiotic treatment decisions: Evaluating rapid molecular diagnostics to identify susceptibility and resistance to carbapenems against Acinetobacter spp. in PRIMERS III. J Clin Microbiol 55:134 -144. https://doi.org/10.1128/JCM.01524-16.
7. Ito A, Nishikawa T, Matsumoto S, Yoshizawa H, Sato T, Nakamura R, Tsuji M, Yamano Y. 2016. Siderophore cephalosporin cefiderocol utilizes ferric iron transporter systems for antibacterial activity against Pseudomonas aeruginosa. Antimicrob Agents Chemother 60:7396 -7401. https://doi .org/10.1128/AAC.01405-16.
8. Katsube T, Echols R, Arjona Ferreira JC, Krenz HK, Berg JK, Galloway C. 2017. Cefiderocol, a siderophore cephalosporin for Gram-negative bacterial infections: Pharmacokinetics and safety in subjects with renal impairment. J Clin Pharmacol 57:584 -591. https://doi.org/10.1002/jcph .841.
9. Wright H, Bonomo RA, Paterson DL. 2017. New agents for the treatment of infections with Gram-negative bacteria: Restoring the miracle or false dawn? Clin Microbiol Infect 23:704 -712. https://doi.org/10.1016/j.cmi .2017.09.001.
10. Ito A, Kohira N, Bouchillon SK, West J, Rittenhouse S, Sader HS, Rhomberg PR, Jones RN, Yoshizawa H, Nakamura R, Tsuji M, Yamano Y. 2016. In vitro antimicrobial activity of S-649266, a catecholsubstituted siderophore cephalosporin, when tested against nonfermenting Gram-negative bacteria. J Antimicrob Chemother 71: 670-677. https://doi.org/10.1093/jac/dkv402.
11. Ito A, Sato T, Ota M, Takemura M, Nishikawa T, Toba S, Kohira N, Miyagawa S, Ishibashi N, Matsumoto S, Nakamura R, Tsuji M, Yamano Y. 2018. In vitro antibacterial properties of cefiderocol, a novel siderophore cephalosporin, against Gram-negative bacteria. Antimicrob Agents Chemother 62:e01454-17. https://doi.org/10.1128/AAC.01454-17.
12. Matsumoto S, Singley CM, Hoover J, Nakamura R, Echols R, Rittenhouse S, Tsuji M, Yamano Y. 2017. Efficacy of cefiderocol against carbapenemresistant Gram-negative bacilli in immunocompetent-rat respiratory tract infection models recreating human plasma pharmacokinetics. Antimicrob Agents Chemother 61:e00700-17. https://doi.org/10.1128/AAC .00700-17.
13. Ghazi IM, Monogue ML, Tsuji M, Nicolau DP. 2018. Pharmacodynamics of cefiderocol, a novel siderophore cephalosporin, in a Pseudomonas aeruginosa neutropenic murine thigh model. Int J Antimicrob Agents 51:206 -212. https://doi.org/10.1016/j.ijantimicag.2017.10.008.
14. Kawaguchi N, Katsube T, Echols R, Wajima T. 2018. Population pharmacokinetic analysis of cefiderocol, a parenteral siderophore cephalosporin, in healthy subjects, subjects with various degrees of renal function, and patients with complicated urinary tract infection or acute uncomplicated pyelonephritis. Antimicrob Agents Chemother 62:e01391-17. https://doi.org/10.1128/AAC.01391-17.
15. Katsube T, Miyazaki S, Narukawa Y, Hernandez-Illas M, Wajima T. 2018. Drug-drug interaction of cefiderocol, a siderophore cephalosporin, via human drug transporters. Eur J Clin Pharmacol 74:931-938. https://doi .org/10.1007/s00228-018-2458-9.
16. Clinical and Laboratory Standards Institute. 2018. M100-S28. Performance standards for antimicrobial susceptibility testing, 28th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
17. Clinical and Laboratory Standards Institute. 2018. M07. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 11th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
18. Huband MD, Ito A, Tsuji M, Sader HS, Fedler KA, Flamm RK. 2017. Cefiderocol MIC quality control ranges in iron-depleted cation-adjusted Mueller-Hinton broth using a CLSI M23-A4 multi-laboratory study design. Diagn Microbiol Infect Dis 88:198 -200. https://doi.org/10.1016/j .diagmicrobio.2017.03.011.
19. Henig O, Cober E, Richter SS, Perez F, Salata RA, Kalayjian RC, Watkins RR, Marshall S, Rudin SD, Domitrovic TN, Hujer AM, Hujer KM, Doi Y, Evans S, Fowler VG, Jr, Bonomo RA, van Duin D, Kaye KS, Antibacterial Resistance Leadership Group. 2017. A prospective observational study of the epidemiology, management, and outcomes of skin and soft tissue infections due to carbapenem-resistant Enterobacteriaceae. Open Forum Infect Dis 4:ofx157. https://doi.org/10.1093/ofid/ofx157.
20. Mojica MF, Papp-Wallace KM, Taracila MA, Barnes MD, Rutter JD, Jacobs MR, LiPuma JJ, Walsh TJ, Vila AJ, Bonomo RA. 2017. Avibactam restores the susceptibility of clinical isolates of Stenotrophomonas maltophilia to aztreonam. Antimicrob Agents Chemother 61:e00777-17. https://doi.org/10.1128/AAC.00777-17.
21. Evans SR, Tran TTT, Hujer AM, Hill CB, Hujer KM, Mediavilla JR, Manca C, Domitrovic TN, Perez F, Farmer M, Pitzer KM, Wilson BM, Kreiswirth BN, Patel R, Jacobs MR, Chen L, Fowler VG, Jr, Chambers HF, Bonomo RA, Antibacterial Resistance Leadership Group. 20 September 2018. Rapid molecular diagnostics to inform empiric use of ceftazidime/avibactam and ceftolozane/tazobactam against Pseudomonas aeruginosa: PRIMERS IV. Clin Infect Dis https://doi.org/10.1093/cid/ciy801.
22. Perez F, Hujer AM, Marshall SH, Ray AJ, Rather PN, Suwantarat N, Dumford D, O'Shea P, Domitrovic TNJ, Salata RA, Chavda KD, Chen L, Kreiswirth BN, Vila AJ, Haussler S, Jacobs MR, Bonomo RA. 2014. Extensively drug-resistant Pseudomonas aeruginosa isolates containing blaVIM-2 and elements of Salmonella genomic island 2: A new genetic resistance determinant in northeast Ohio. Antimicrob Agents Chemother 58:5929 -5935. https://doi.org/10.1128/AAC.02372-14.
23. Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, Lesin VM, Nikolenko SI, Pham S, Prjibelski AD, Pyshkin AV, Sirotkin AV, Vyahhi N, Tesler G, Alekseyev MA, Pevzner PA. 2012. SPAdes: A new genome assembly algorithm and its applications to single-cell sequencing. J Comput Biol 19:455- 477. https://doi.org/10.1089/cmb.2012.0021.
24. Tatusova T, DiCuccio M, Badretdin A, Chetvernin V, Nawrocki EP, Zaslavsky L, Lomsadze A, Pruitt KD, Borodovsky M, Ostell J. 2016. NCBI prokaryotic genome annotation pipeline. Nucleic Acids Res 44: 6614-6624. https://doi.org/10.1093/nar/gkw569.
25. Endimiani A, Hujer AM, Perez F, Bethel CR, Hujer KM, Kroeger J, Oethinger M, Paterson DL, Adams MD, Jacobs MR, Diekema DJ, Hall GS, Jenkins SG, Rice LB, Tenover FC, Bonomo RA. 2009. Characterization of blaKPC-containing Klebsiella pneumoniae isolates detected in different institutions in the eastern USA. J Antimicrob Chemother 63:427- 437. https://doi.org/10.1093/jac/dkn547.
26. Poirel L, Walsh TR, Cuvillier V, Nordmann P. 2011. Multiplex PCR for detection of acquired carbapenemase genes. Diagn Microbiol Infect Dis 70:119 -123. https://doi.org/10.1016/j.diagmicrobio.2010.12.002.
27. Kohira N, West J, Ito A, Ito-Horiyama T, Nakamura R, Sato T, Rittenhouse S, Tsuji M, Yamano Y. 2016. In vitro antimicrobial activity of a siderophore cephalosporin, S-649266, against Enterobacteriaceae clinical isolates, including carbapenem-resistant strains. Antimicrob Agents Chemother 60:729 -734. https://doi.org/10.1128/AAC.01695-15.
28. Dobias J, Denervaud-Tendon V, Poirel L, Nordmann P. 2017. Activity of the novel siderophore cephalosporin cefiderocol against multidrugresistant Gram-negative pathogens. Eur J Clin Microbiol Infect Dis 36: 2319-2327. https://doi.org/10.1007/s10096-017-3063-z.
29. Hackel MA, Tsuji M, Yamano Y, Echols R, Karlowsky JA, Sahm DF. 2017. In vitro activity of the siderophore cephalosporin, cefiderocol, against a recent collection of clinically relevant Gram-negative bacilli from North America and Europe, including carbapenem-nonsusceptible isolates (SIDERO-WT-2014 Study). Antimicrob Agents Chemother 61:e00093-17. https://doi.org/10.1128/AAC.00093-17.
30. Hackel MA, Tsuji M, Yamano Y, Echols R, Karlowsky JA, Sahm DF. 2018. In vitro activity of the siderophore cephalosporin, cefiderocol, against carbapenem-nonsusceptible and multidrug-resistant isolates of Gramnegative bacilli collected worldwide in 2014 to 2016. Antimicrob Agents Chemother 62:e01968-17. https://doi.org/10.1128/AAC.01968-17.